News Release(2020)

2020
-
December 10, 2020
The Efficacy and Safety Results of the Overseas Phase-III Long-Term Study of Uterine Fibroids for GnRH Antagonist, Linzagolix, conducted by ObsEva
-
October 9, 2020
Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease
-
July 6, 2020
Positive Results from Uterine Fibroids Phase-III Clinical Trials (PRIMROSE 1 and PRIMROSE 2) of Linzagolix
-
March 27, 2020
Licensing Agreement for CG0070, a Drug for Bladder Cancer
-
February 25, 2020
Transfer of Distribution Operation of MINIRIN MELT® and DESMOPRESSIN Formulations
-
February 3, 2020
Transfer of Distribution Operation of MARIZEV® Type-2 Diabetes Treatment
-
January 22, 2020
Kissei Announces the Publication of the Results of Phase III Clinical Trials of Rovatirelin for the Treatment of Spinocerebellar Degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry